Intramyocardial injection of mitochondria-rich extracellular vesicles significantly improved post-MI cardiac function through restoration of bioenergetics and mitochondrial biogenesis in a murine model.
Do mitochondria-rich extracellular vesicles from autologous stem cell-derived cardiomyocytes restore energetics and improve cardiac function in ischemic myocardium models?
Mitochondria-rich extracellular vesicles from stem cell-derived cardiomyocytes restore bioenergetics and improve cardiac function in preclinical models of myocardial ischemia.
BACKGROUND: Mitochondrial dysfunction results in an imbalance between energy supply and demand in a failing heart. An innovative therapy that targets the intracellular bioenergetics directly through mitochondria transfer may be necessary. OBJECTIVES: The purpose of this study was to establish a preclinical proof-of-concept that extracellular vesicle (EV)-mediated transfer of autologous mitochondria and their related energy source enhance cardiac function through restoration of myocardial bioenergetics. METHODS: Human-induced pluripotent stem cell-derived cardiomyocytes (iCMs) were employed. iCM-conditioned medium was ultracentrifuged to collect mitochondria-rich EVs (M-EVs). Therapeutic effects of M-EVs were investigated using in vivo murine myocardial infarction (MI) model. RESULTS: Electron microscopy revealed healthy-shaped mitochondria inside M-EVs. Confocal microscopy showed that M-EV-derived mitochondria were transferred into the recipient iCMs and fused with their endogenous mitochondrial networks. Treatment with 1.0 × 108/ml M-EVs significantly restored the intracellular adenosine triphosphate production and improved contractile profiles of hypoxia-injured iCMs as early as 3 h after treatment. In contrast, isolated mitochondria that contained 300× more mitochondrial proteins than 1.0 × 108/ml M-EVs showed no effect after 24 h. M-EVs contained mitochondrial biogenesis-related messenger ribonucleic acids, including proliferator-activated receptor γ coactivator-1α, which on transfer activated mitochondrial biogenesis in the recipient iCMs at 24 h after treatment. Finally, intramyocardial injection of 1.0 × 108 M-EVs demonstrated significantly improved post-MI cardiac function through restoration of bioenergetics and mitochondrial biogenesis. CONCLUSIONS: M-EVs facilitated immediate transfer of their mitochondrial and nonmitochondrial cargos, contributing to improved intracellular energetics in vitro. Intramyocardial injection of M-EVs enhanced post-MI cardiac function in vivo. This therapy can be developed as a novel, precision therapeutic for mitochondria-related diseases including heart failure.
Ikeda et al. (Mon,) conducted a other in Myocardial infarction. Mitochondria-rich extracellular vesicles (M-EVs) vs. Isolated mitochondria was evaluated on Restoration of intracellular ATP production, contractile profiles, and post-MI cardiac function. Intramyocardial injection of mitochondria-rich extracellular vesicles significantly improved post-MI cardiac function through restoration of bioenergetics and mitochondrial biogenesis in a murine model.